Stockpolly
Search
Delisting risk
ONCO · NASDAQ · Biotechnology

Onconetix (ONCO)

Prostate-cancer diagnostics developer centered on the Proclarix blood test.

$0.6847
Pre-market−0.00 (−0.04%)
At close$0.6850(+4.93%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue001101000000
Cost of revenue011100000000
Gross profit0−10001000000
441114330212223
Research & development000000000000
444233222222
General & administrative400000000000
Other expenses00711027000000
Operating income−4−5−11−14−3−29−2−1−2−1−2−3
−1−170−1−1−1−7−1−77−20
Interest income000000000000
Interest expense000000000000
Other non-operating income1170011716−720
Income before tax−5−22−11−14−4−30−9−2−96−4−3
Income tax expense00000−1000000
Net income from continuing operations−5−22−11−14−4−29−9−2−96−4−3
Net income−5−22−11−14−4−29−9−2−96−4−3
EPS, basic−$0.09−$0.29−$0.14−$0.18−$0.84−$4.97−$514.86−$1.36−$1.79$1.04−$6.71−$1.28
EPS, diluted−$0.09−$0.29−$0.14−$0.18−$0.84−$4.97−$514.86−$1.36−$1.79$1.04−$6.71−$1.28
Weighted average shares, basic00—00012—312
Weighted average shares, diluted00—00012—312
EBITDA−5−22−11−14−3−30−8−2−86−4−3
Depreciation & amortization000000000000
EBIT−5−22−11−14−3−30−8−2−86−4−3